A Study for Patients With Schizophrenia

NCT00520923 ↗

Phase 2 Completed 654 enrolled Eli Lilly and Company

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to test the hypothesis that 1 or more dose levels of LY2140023 given orally to patients with schizophrenia twice daily for 4 weeks will have significantly greater effect than placebo.

Timeline

Start: 2007-09
Primary completion: 2008-10
Completion: 2008-10

Publications

Kinon BJ, Millen BA, Zhang L, McKinzie DL. Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia. Biol Psychiatry. 2015 Dec 1;78(11):754-62. doi: 10.1016/j.biopsych.2015.03.016. Epub 2015 Mar 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LY2140023	Unknown	5 mg	Oral
Subject	LY2140023	Unknown	20 mg	Oral
Subject	LY2140023	Unknown	40 mg	Oral
Subject	LY2140023	Unknown	80 mg	Oral
Comparator	Olanzapine	Small molecule	15 mg	Oral

A Study for Patients With Schizophrenia

Summary

Timeline

Publications

Drugs

Indications